Dermata Therapeutics, Inc. (DRMAW)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 617,835 | |||
| General and administrative | 1,154,896 | |||
| Total operating expenses | 1,772,731 | |||
| Loss from operations | -1,772,731 | |||
| Interest income | 71,638 | |||
| Net loss | -1,701,093 | |||
| Net loss per share of common stock, basic | -1.66 | |||
| Net loss per share of common stock, diluted | -1.66 | |||
| Weighted-average basic common stock | 1,026,506 | |||
| Weighted-average diluted common stock | 1,026,506 | |||